Navigation Links
InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
Date:11/6/2008

neral and

administrative 7,879 6,380 22,465 22,966

Acquired research and

development milestone - 7,500 - 7,500

Restructuring charges - 317 - 10,246

Total costs and

expenses 35,236 41,126 108,048 133,596

Loss from operations (11,913) (29,755) (67,297) (76,531)

Interest income 1,212 2,510 4,644 7,754

Interest expense (1,520) (726) (4,101) (2,185)

Other income (expense) 18 (196) 1,286 2,326

Loss from continuing

operations before income

taxes (12,203) (28,167) (65,468) (68,636)

Income tax expense 325 - - -

Loss from continuing

operations (12,528) (28,167) (65,468) (68,636)

Discontinued operations:

Income (loss) from

discontinued operations (3) 5,043 71 4,915

Net loss $(12,531) $(23,124) $(65,397) $(63,721)

Basic and diluted loss per

share:

Continuing operations $(0.32) $(0.81) $(1.68) $(1.99)

Discontinued operations - 0.15 - 0.14

Net loss per share $(0.32) $(0.66) $(1.68) $(1.85)

Shares used in computing

basic and diluted net loss

per share 39,031 34,801 38,954 34,394

InterMune, Inc.

PRELIMINARY CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited, in thousands)

Sept 3
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...--ShanghaiBiolaxyannouncedthe,ChineseStateFood&...ionalnewdrugapplication(IND)foritsoralinsulinproje...iabetes.ThisIND,approvalallowsBiolaxytoinitiateits...ercharacteristicofhighbloodglucoseandpoor,metaboli...cro-and,macro-vasculardiseases,lossofvision,kidney...
(Date:11/24/2009)...ly approved the Promega PowerPlex 16 HS System for...g DNA records for the National DNA Index System. ...-- The FBI recently approved the Promega PowerPle...cipating in, or generating DNA records for, the Na...tains more than seven million profiles and has ass...
(Date:11/24/2009)...v.24/PRNewswire-FirstCall/-HamiltonThorneLtd.(TSX-...ofadvancedlasersystemsandinstrumentsforthestemcell...rationalandfinancialresultsforthethirdquarterended...s$1.46millioncomparedwith$1.43millioninQ32008,-Gro...tinQ3,2008,-Netlossreducedto$148,000comparedto$283...
(Date:11/24/2009)...FirstCall/--ArenaPharmaceuticals,Inc.(Nasdaq: ARNA...ntatthePiperJaffray21stAnnualHealthCareConferenceo...ficTime)attheNewYorkPalaceHotelinNewYorkCity.JackL...cheduledtoprovideanoverviewofthecompany,includingi...liveaudiowebcastofthepresentationwillbeavailableun...
Breaking Biology Technology:Biolaxy Secures IND Approval for Oral Insulin 2NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2
...lhi based Mayuka Labs,Private Limited has received...opment facility from the department of scientific ...of science and technology, Government of,India. , ...lock at its R&D and Pilot,unit at Nacharam, Ma...year of,operations. The company has filed two inte...
... Victhom Human Bionics Inc., "Victhom" (TSX: VHB),...t for the detection and treatment of sleep apnea a... its preclinical studies. , The Company has recent...thod and device for the detection, identification ...uromodulation platform. Late in 2007, the Company ...
...(OTC: NNLX) a biotechnology company, announces dir... , , NanoLogix welcomes Daniel Barnhizer and Jef... is an associate professor of law at Michigan Sta...d writes in the areas of business, contract, secur...emic work, Professor Barnhizer also maintains an a...
Other Biology Technology:Mayuka Labs R&D Centre Gets DSIR Recognition 2Victhom announces the completion of the second phase of the apnea therapy development 2Victhom announces the completion of the second phase of the apnea therapy development 3NanoLogix Inc. Appoints Two New Directors and Provides Operations Update 2NanoLogix Inc. Appoints Two New Directors and Provides Operations Update 3
(Date:11/23/2009)...veal in unprecedented detail how the ribosome inte...s and guide them toward their destination in biolo...lexible fitting (MDFF) to examine the interaction ...ers. , The first study, in Proceedings of the ...te signaling between the ribosome and an elongatio...
(Date:11/23/2009)...e existed for 360 million years and survived when ...threatening to make many of them extinct, accordin...logy Today . , The fungus, Batrachochytrium de... waves of amphibian extinctions in Central America...ects over 350 amphibian species by penetrating the...
(Date:11/23/2009)...nder of six-week-old turkey poults could save mill...r birth, according to Dr. Gerald Steiner from the ...s team. Their use of infrared spectroscopy to dete... fast and accurate method with the potential to be...ect female eggs for breeding. The pilot study has ...
Breaking Biology News(10 mins):Computational microscope peers into the working ribosome 2Computational microscope peers into the working ribosome 3Rescuing male turkey chicks 2Grubb 26 Ellis Healthcare REIT II Declared Effective by the U S Securities and Exchange Commission 55245 1Consolidation Among Chicago Physicians Likely to Increase 55243 1Consolidation Among Chicago Physicians Likely to Increase 55243 2Consolidation Among Chicago Physicians Likely to Increase 55243 3Hypertension Drug Market Will Experience Only Modest Annual Decline Through 2018 Despite Generic Erosion Of Many Branded Agents 13678 1Hypertension Drug Market Will Experience Only Modest Annual Decline Through 2018 Despite Generic Erosion Of Many Branded Agents 13678 2
... worlds leading STM publishers, has signed publish...societies during the past half year. With this mo...tive selection of Korean society journals and conf...g the increasing amount of research coming from As...ls in 2008 were signed with the Korean Society of ...
...(NGF), as the name says, is an essential peptide f...al cells. Therefore we can imagine that this growt...ding brain. But a recent scientific report publish...Gastroenterology tells us another surprising and e... positively related with liver cancer, the No.2 ki...
... Scientists know that inside each cell, a little ... job: It copies instructions from genes in the nuc...est of the cell to support our daily needs. Now re...hool have shown that RNA polymerase II also consta...types of damage in DNA halt the action of RNA poly...
Other Biology News:Targeting nerve growth factor may cure liver cancer 2Enzyme alerts cell's powerful army to repair DNA damage 2Enzyme alerts cell's powerful army to repair DNA damage 3
... 2, Monoclonal Antibody, Unconjugated Applicati...ICC: Use at an assay dependent dilution. WB: Use a...ion is determined using a whole extract of rat bra... in other applications. Optimal dilutions/concent...
Mouse Anti-G alpha o Monoclonal Antibody, Unconjugated, Clone 1C.2 from Sigma-Aldrich
Anti-SHP-2 Antibody, Unconjugated from Cell Signaling Technology
Mouse Anti-Human PPAR gamma 2 Monoclonal Antibody, Unconjugated, Clone K8450B from Cosmo Bio Co., Ltd.
Biology Products: